The effect of p22-PHOX (CYBA) polymorphisms on premature coronary artery disease (≤ 40 years of age)

Summary Acute myocardial infarction at a young age is associated with high morbidity and long-term mortality. The NADPH oxidase system as a main source of reactive oxygen species in vascular cells has been implicated in development and progression of coronary artery disease (CAD). In our study, we investigated the effect of polymorphisms in the p22-PHOX (CYBA) gene on CAD in young patients (≤ 40 years). We prospectively recruited 302 subjects into our multi-centre case control study, including 102 young myocardial infarction patients (≤ 40 years) from two high-volume cardiac catheterisation hospitals and frequency-matched them on age, gender, and center to 200 hospital controls in an approximate 2:1 ratio per case patient. The homozygote c.-930A>G promoter polymorphism was significantly more prevalent in the controls than in the infarction patients. In the adjusted logistic regression analysis, we detected a protective effect of the c.-930A>G promoter polymorphism against premature myocardial infarction. Using a logadditive/per-allele model, we detected an unadjusted odds ratio (OR) of 0.63 (95% confidence interval [CI] 0.45–0.9, p-value 0.011). In the adjusted model the association was more pronounced with an OR of 0.5 (95% CI 0.3–0.81, p-value 0.005). The C242T polymorphism and the 640A>G polymorphism did not differ significantly between the study groups. Furthermore we could not detect a significant effect for these polymorphisms in the logistic regression analysis. The present study suggests a protective association between the c.-930A>G promoter polymorphism in the p22-PHOX (CYBA) gene and the development of myocardial infarction in young individuals (≤ 40 years).

[1]  G. Maurer,et al.  Elevated risk of myocardial infarction in very young immigrants from former Yugoslavia , 2009, European Journal of Epidemiology.

[2]  O. Wagner,et al.  Familial-combined hyperlipidaemia in very young myocardial infarction survivors (< or =40 years of age). , 2009, European heart journal.

[3]  A. Castelnuovo,et al.  The C242T polymorphism of the p22phox component of NAD (P)H oxidase and vascular risk , 2008, Thrombosis and Haemostasis.

[4]  Fred S Apple,et al.  Universal definition of myocardial infarction. , 2007, Journal of the American College of Cardiology.

[5]  L. Tavazzi,et al.  Metabolic syndrome and risk of cardiovascular events after myocardial infarction. , 2005, Journal of the American College of Cardiology.

[6]  Hua Tang,et al.  Inactivation of Src Family Tyrosine Kinases by Reactive Oxygen Species in Vivo* , 2005, Journal of Biological Chemistry.

[7]  R. de Caterina,et al.  Oxidative stress and cardiovascular risk: the role of vascular NAD(P)H oxidase and its genetic variants , 2005, European journal of clinical investigation.

[8]  A. Cayuela,et al.  Long-term prognosis of patients having acute myocardial infarction when , 2004, The American journal of cardiology.

[9]  J. Díez,et al.  Functional Effect of the p22phox −930A/G Polymorphism on p22phox Expression and NADPH Oxidase Activity in Hypertension , 2004, Hypertension.

[10]  L. Becker New concepts in reactive oxygen species and cardiovascular reperfusion physiology. , 2004, Cardiovascular research.

[11]  J. Paramo,et al.  Preliminary characterisation of the promoter of the human p22phox gene: identification of a new polymorphism associated with hypertension , 2003, FEBS letters.

[12]  T. Miyatsuka,et al.  Association of NAD(P)H oxidase p22 phox gene variation with advanced carotid atherosclerosis in Japanese type 2 diabetes. , 2003, Diabetes care.

[13]  G. Zalba,et al.  Polymorphisms and Promoter Overactivity of the p22 phox Gene in Vascular Smooth Muscle Cells From Spontaneously Hypertensive Rats , 2001, Circulation research.

[14]  K. Channon,et al.  Functional Effect of the C242T Polymorphism in the NAD(P)H Oxidase p22phox Gene on Vascular Superoxide Production in Atherosclerosis , 2000, Circulation.

[15]  S. Zahler,et al.  Endothelial preconditioning by transient oxidative stress reduces inflammatory responses of cultured endothelial cells to TNF‐α , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  D. Sanghera,et al.  The p22 phox polymorphism C242T is not associated with CHD risk in Asian Indians and Chinese , 1999, European journal of clinical investigation.

[17]  A. Quyyumi,et al.  Relationship of the C242T p22phox gene polymorphism to angiographic coronary artery disease and endothelial function. , 1999, American journal of medical genetics.

[18]  Cai,et al.  NADH/NADPH oxidase p22phox C242T polymorphism and coronary artery disease in the Australian population , 1999, European journal of clinical investigation.

[19]  A. Gardemann,et al.  The p22 phox A640G gene polymorphism but not the C242T gene variation is associated with coronary heart disease in younger individuals. , 1999, Atherosclerosis.

[20]  K. Kanazawa,et al.  Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. , 1998, Circulation.

[21]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[22]  J. Hill,et al.  Myocardial infarction in the young and in women. , 1989, Cardiovascular clinics.

[23]  W D Dupont,et al.  Power calculations for matched case-control studies. , 1988, Biometrics.